Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

British Journal of Haematology

Volumn 115, Issue 3, 2001, Pages 605-608

  Neben, Kai ^a   Moehler, Thomas ^a   Kraemer, Alwin ^a   Benner, Axel ^b   Egerer, Gerlinde ^a   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Multiple myeloma; Thalidomide; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 6; SCATTER FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035672117     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03142.x     Document Type: Article

References (12)

1. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
2. Interleukin 6 induces the expression of vascular endothelial growth factor
3. Thalidomide is an inhibitor of angiogenesis
4. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumour microenvironment
5. Tumour necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo
6. Synergistic effects of vascular endothelial growth factor and basic fibrinoblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
7. Thalidomide - A revival story
8. Prognostic value of bone marrow angiogenesis in multiple myeloma
9. A high pretretment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
10. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma
11. Antitumour activity of thalidomide in refractory multiple myeloma
12. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma